1. Home
  2. TRST vs ABUS Comparison

TRST vs ABUS Comparison

Compare TRST & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TrustCo Bank Corp NY

TRST

TrustCo Bank Corp NY

HOLD

Current Price

$47.57

Market Cap

834.0M

Sector

Finance

ML Signal

HOLD

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

HOLD

Current Price

$4.40

Market Cap

929.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRST
ABUS
Founded
1902
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
834.0M
929.6M
IPO Year
1994
2008

Fundamental Metrics

Financial Performance
Metric
TRST
ABUS
Price
$47.57
$4.40
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$5.00
AVG Volume (30 Days)
67.9K
2.0M
Earning Date
04-21-2026
05-14-2026
Dividend Yield
3.25%
N/A
EPS Growth
26.46
55.26
EPS
3.25
N/A
Revenue
N/A
$14,083,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$239.71
P/E Ratio
$14.58
N/A
Revenue Growth
N/A
128.21
52 Week Low
$30.17
$3.04
52 Week High
$48.45
$5.10

Technical Indicators

Market Signals
Indicator
TRST
ABUS
Relative Strength Index (RSI) 64.22 55.41
Support Level $44.46 $4.19
Resistance Level N/A $4.64
Average True Range (ATR) 1.27 0.18
MACD 0.14 0.01
Stochastic Oscillator 100.00 67.57

Price Performance

Historical Comparison
TRST
ABUS

About TRST TrustCo Bank Corp NY

Trustco Bank Corp N Y is a savings and loan holding company. The core part of a business consists of accepting deposits and making loans and investments. It offers a range of both personal and business banking services. The company's product includes savings accounts; retirement accounts; money market account; mortgages; building loans; auto loans and others. The company derives revenue from the business of Banking. TrustCo lends in the geographic territory of its branch locations in New York, Florida, Massachusetts, New Jersey, and Vermont.

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Share on Social Networks: